Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients
Status:
Terminated
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
To evaluate the effect of re-administration of gefitinib to EGFR-mutated NSCLC patients who
had been treated with at least one line of TKIs followed by another line of treatment
(non-TKI)